On Thursday, Alcatel Lucent SA (ADR) (NYSE:ALU)’s shares declined -0.54% to $3.65.
Alcatel-Lucent (ALU) has accomplished another industry leading step on the path to delivering 5G netoperates. As declared recently, the 5GNOW project, with technical leadership by Alcatel-Lucent, has been awarded the highest scientific excellence honor by the European Commission for advancing development of the next generation of mobile netoperates (5G) and strengthening European competitiveness. The project, initiated in 2012, was accomplished this month and delivered a big step toward achieving 5G netoperates.
In just a few years mobile netoperates are predictable to support billions of different devices and types of data traffic. Recently’s netoperates can support applications such as video and file downloads, however they were not designed with the flexibility to also support the predictable myriad new applications. 5G netoperates must be designed to flexibly support this video traffic while also supporting the ongoing growth of smartphone and tablet traffic, low-end sensor devices, smart wearables, connected cars, and the connection of industrial robots across wide geographical areas. New innovations, such as those pioneered by Alcatel-Lucent’s Bell Labs in the 5GNOW project, will allow new communications to support the wide variety of application demanded.
Alcatel-Lucent provides Internet protocol (IP) and cloud networking, and ultra- broadband access worldwide. The company’s Core Networking segment offers IP routing, carrier Ethernet, network functions virtualization, and software defined networking applications and infrastructure to meet the challenges of network traffic growth while supporting the delivery of cloud-enabled business, mobile, and residential services for service providers, mobile network operators, cable/multiple system operators, transportation, utilities, and large-scale enterprises.
Bristol-Myers Squibb Co (NYSE:BMY)’s shares dropped -2.34% to $63.54.
Bristol-Myers Squibb Company (BMY) declared a charitable donation to The Leukemia & Lymphoma Society (LLS). The donation will provide financial assistance for chronic myeloid leukemia (CML) patients who need assist paying for Polymerase Chain Reaction (PCR) testing, an important tool used in the diagnosis and monitoring of CML. The donation will also support LLS CML awareness activities focused on educating patients, caregivers and healthcare providers about the importance of continued monitoring with PCR testing.
The PCR test is used both in the diagnosis of CML and to monitor for cancerous cells after treatment has begun. It is the most sensitive testing method accessible, with the ability to detect a single cancerous cell among one million healthy cells. Recommendations suggest that a CML patient should receive a PCR test every three months for the first three years after diagnosis, and every three to six months thereafter based on how well their treatment is working. The average cost of a PCR test is $345 and can be as high as $500 per test. The program will assist insured and uninsured patients with out-of-pocket costs for PCR testing. The donation will also fund national CML awareness activities that will be undertaken by LLS’s 56 chapters, in addition to grassroots efforts through local netoperates of patients, volunteers and healthcare institutions.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
At the end of Thursday’s trade, Ultra Petroleum Corp. (NYSE:UPL)‘s shares surged 9.15% to $7.04.
Ultra Petroleum Corp. (UPL) continued to deliver strong financial and operating performance for the second quarter of 2015. Highlights comprise:
- Produced volumes of 70.5 Bcfe of natural gas and oil, an enhance of 20% above year ago levels
- Generated operating cash flow(1)of $121.9 million for the quarter ended June 30, 2015
- Earnings of $32.1 million in the second quarter of 2015, or $0.21 per diluted share – adjusted(2)
- 47 percent cash flow margin(4)for the second quarter of 2015
Second Quarter Results
Ultra Petroleum stated adjusted net income(2) of $32.1 million, or $0.21 per diluted share for the second quarter of 2015. Operating cash flow(1) was $121.9 million for the quarter ended June 30, 2015.
For the second quarter of 2015, production of natural gas and oil was 70.5 billion cubic feet equivalent (Bcfe). The company’s production for the second quarter was comprised of 65.1 billion cubic feet (Bcf) of natural gas and 900.0 thousand barrels (Mbls) of oil and condensate.
During the second quarter of the year, Ultra Petroleum’s average realized natural gas price was $3.33 per thousand cubic feet (Mcf), counting realized gains and losses on commodity hedges. Not taking into account realized gains and losses on commodity derivatives, the company’s average price for natural gas was $2.52 per Mcf. The company’s average realized oil and condensate price was $48.64 per barrel (Bbl).
Second quarter 2015 results comprised of an unrealized, mark-to-market loss of $56.3 million on the company’s commodity hedges. The unrealized loss is typically excluded by the investment community in published estimates.
Ultra Petroleum Corp., an independent oil and gas company, engages in the acquisition, exploration, development, production, and operation of oil and natural gas properties in the United States. It primarily focuses on developing natural gas reserves in the Green River Basin of Wyoming; oil reserves in the Uinta Basin of Utah; and natural gas reserves in the Appalachian Basin of Pennsylvania.
Agnico Eagle Mines Ltd (USA) (NYSE:AEM), ended its Thursday’s trading session with 3.93% gain, and closed at $21.93.
Agnico Eagle Mines Limited (AEM) stated quarterly net income of $10.1 million , or net income of $0.05 per share for the second quarter of 2015. This result comprises non-recurring losses of $12.9 million ( $0.06 per share), unrealized gains on financial instruments of $9.4 million ( $0.04 per share), non-cash foreign currency translation losses of $4.8 million ( $0.02 per share), non-cash stock option expense of $4.1 million ( $0.02 per share), a non-cash foreign currency translation gain on deferred tax liabilities of $3.2 million ( $0.01 per share) and various mark-to-market and other adjustment gains of $0.8 million ( $0.01 per share). Not taking into account these items would result in adjusted net income of $18.5 million or adjusted net income of $0.09 per share for the second quarter of 2015. In the second quarter of 2014, the Company stated net income of $22.2 million or net income of $0.12 per share.
For the first six months of 2015, the Company stated net income of $38.8 million , or $0.18 per share. This compares with the first six months of 2014 when net income was $119.3 million , or $0.66 per share. Financial results in the 2015 period were negatively influenced by lower gold prices (about 8% lower) and lower by-product metals revenues.
Agnico Eagle Mines Limited engages in the exploration, development, and production of mineral properties. It primarily explores for gold, in addition to for silver, copper, zinc, and lead. The company’s flagship property comprises the LaRonde mine, which comprises a 100% owned LaRonde property that comprises of 36 contiguous mining claims and 1 provincial mining lease covering 1,047.4 hectares; El Coco property, which comprises 22 contiguous mining claims and 1 provincial mining lease comprising 356.7 hectares; and Terrex property that comprises 21 mining claims and 1 provincial mining lease covering 424.4 hectares, in addition to 3 surface rights leases covering in total of about 303.6 hectares in northwestern Quebec.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
